An AI Drug Developer Flies Under the Radar

Published by
The Street

By Maxx Chatsko Investors may be familiar with more prominent drug developers, but this small-cap biotech shouldn’t be overlooked. The inefficiency of drug development is well documented, but let’s put some numbers on it. Less than 8% of drug candidates that enter Phase 1 clinical trials earn regulatory approval. That suggests companies are doing a poor job tackling the complexity of biology. Indeed, a survey published in Nature 2016 found that more than 80% of chemists and biologists couldn’t reproduce the results from peer-reviewed papers – generally accepted as the gold standard of scientif…

Read More

See also  Here's What Social Media Had to Say About Apple's Big Event

Leave a Reply